Modality
Peptide
MOA
JAK1i
Target
RET
Pathway
Autophagy
PsANB
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Jul 2031
Phase 3Current
NCT03522338
484 pts·PsA
2017-05→TBD·Completed
NCT07499283
2,029 pts·PsA
2018-04→2031-05·Not yet recruiting
NCT05168772
799 pts·PsA
2017-08→2028-12·Recruiting
+1 more trial
6,147 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2028-12-172.7y awayPh3 Readout· PsA
2031-05-075.1y awayPh3 Readout· PsA
2031-07-035.3y awayPh3 Readout· NB
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Complet…
P3
Recruit…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2028-12-17 · 2.7y away
PsA
Ph3 Readout
2031-05-07 · 5.1y away
PsA
Ph3 Readout
2031-07-03 · 5.3y away
NB
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03522338 | Phase 3 | PsA | Completed | 484 | EFS |
| NCT07499283 | Phase 3 | PsA | Not yet recr... | 2029 | Safety |
| NCT05168772 | Phase 3 | PsA | Recruiting | 799 | NT-proBNP |
| NCT04258972 | Phase 3 | NB | Recruiting | 2835 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-1924 | Argenx | Preclinical | DLL3 |